Eli Lilly developed the diabetes and obesity drug brand Mounjaro.
Mounjaro is the brand name for tirzepatide when prescribed for type 2 diabetes. Eli Lilly developed tirzepatide, a medicine that acts on receptors related to the hormones GIP and GLP-1. The company also markets tirzepatide for chronic weight management under the Zepbound brand in the United States.
Eli Lilly was founded in 1876 in Indianapolis by Colonel Eli Lilly, a pharmaceutical chemist and Union veteran. The company became one of the world’s largest drugmakers, with products spanning diabetes, oncology, immunology, neuroscience, and other fields.
Mounjaro and Zepbound are related but are not interchangeable brand names in every regulatory setting: their approved uses and labeling depend on the jurisdiction. The company’s rapid growth in metabolic medicines helped make it a major constituent of global large-cap stock indexes and one of the most valuable drugmakers.